Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (7284)	9/23/1998 1:38:00 PM
From: Arthur Radley	Respond to of 17367

Agree with your points of concern. As for the menigitis(sp) season, it has already started here in the Houston area with the first case reported on the news last night. A young school girl.

To: LarryS who wrote (7284)	9/23/1998 2:17:00 PM
From: aknahow	Respond to of 17367

It's not for P.R. motives. Think it's obvious XOMA would like to stop and get going with production as soon as possible not only for profit but because they believe the drug will work and save lives and of course create a good impression among practitioners, because of this. XOMA cannot say we expect the final review to call for an early halt. So that is why the explanation is vague. I can't say it will either simply because I do not know. But now I do know that at least an early halt is possible. Such a halt would save 90 days not 30. The DSMB recommendation is based on an analysis of data for subjects for which the 90 day follow up period has been completed. It does not include, (to my knowledge), data for those who have not terminated this 90 day period. The recommendation could be to go into the FDA but give Neuprex to all new subjects rather than a placebo to half of them. Or it could be to simply open up the trial. (Not sure, why) In any event 90 days is a significant saving if things work out that way.